MDRNA, the Bothell, WA-based biotech company, said today it has received a $1 million milestone payment from San Diego-based Amylin Pharmaceuticals under an amended agreement to develop a nasally-delivered version of exenatide, a diabetes drug. MDRNA, formerly known as Nastech Pharmaceutical, used to specialize in nasal delivery before it switched its strategy in June to develop RNA interference drugs. The money comes at a critical time, as MDRNA (NASDAQ: [[ticker:MRNA]]) has run low on cash.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
